BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. Journal of Hepatology 2003;38:69-89. [DOI: 10.1016/s0168-8278(03)00007-2] [Cited by in Crossref: 188] [Cited by in F6Publishing: 43] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Christos P, Paraskevi K, Konstantinos P, Katsaraki A, Tsianos EV. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig Dis Sci. 2005;50:1771-1777. [PMID: 16187171 DOI: 10.1007/s10620-005-2935-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Deep A, Saxena R, Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol 2019;34:45-59. [PMID: 29497824 DOI: 10.1007/s00467-018-3893-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
3 Urrunaga NH, Mindikoglu AL, Rockey DC. Renal dysfunction in cirrhosis. Curr Opin Gastroenterol 2015;31:215-23. [PMID: 25763790 DOI: 10.1097/MOG.0000000000000168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
4 Dib N, Oberti F, Calès P. Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ 2006;174:1433-43. [PMID: 16682712 DOI: 10.1503/cmaj.051700] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
5 de Oliveira Gomes CG, de Andrade MVM, Guedes LR, Rocha HC, Guimarães RG, Carvalho FAC, Vilela EG. Evaluation of the Biomarkers HMGB1 and IL-6 as Predictors of Mortality in Cirrhotic Patients with Acute Kidney Injury. Mediators Inflamm 2020;2020:2867241. [PMID: 33061824 DOI: 10.1155/2020/2867241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol. 2006;12:1403-1407. [PMID: 16552809 DOI: 10.3748/wjg.v12.i9.1403] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
7 Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014;20:2704-2714. [PMID: 24627607 DOI: 10.3748/wjg.v20.i10.2704] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
8 Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol 2010;16:347-52. [PMID: 21415576 DOI: 10.3350/kjhep.2010.16.4.347] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
9 Vilas-Boas WW, Ribeiro-Oliveira A Jr, Pereira RM, Ribeiro Rda C, Almeida J, Nadu AP, Simões e Silva AC, dos Santos RA. Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol 2009;15:2512-9. [PMID: 19469002 DOI: 10.3748/wjg.15.2512] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
10 Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-428. [PMID: 19669317 DOI: 10.1007/s12072-008-9100-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
11 Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients. Paediatr Drugs 2006;8:1-13. [PMID: 16494508 DOI: 10.2165/00148581-200608010-00001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
12 Donati G, Angeletti A, Gasperoni L, Piscaglia F, Croci Chiocchini AL, Scrivo A, Natali T, Ullo I, Guglielmo C, Simoni P, Mancini R, Bolondi L, La Manna G. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). J Nephrol 2021;34:77-88. [PMID: 32710265 DOI: 10.1007/s40620-020-00799-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013;5:1-10. [PMID: 24696621 DOI: 10.2147/hmer.s9049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
14 Rochling FA, Zetterman RK. Management of Ascites: . Drugs 2009;69:1739-60. [DOI: 10.2165/11316390-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
15 Nasr G, Hassan A, Ahmed S, Serwah A. Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res 2010;1:136-44. [PMID: 21187868 DOI: 10.4103/0975-3583.70914] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
16 Tanaka M, Iwakiri Y. The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis. Cell Mol Gastroenterol Hepatol. 2016;2:733-749. [PMID: 28105461 DOI: 10.1016/j.jcmgh.2016.09.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 8.6] [Reference Citation Analysis]
17 Kim DJ, Kang HS, Choi HS, Cho HJ, Kim ES, Keum B, An H, Kim JH, Seo YS, Kim YS. Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels. Korean J Hepatol. 2011;17:130-138. [PMID: 21757984 DOI: 10.3350/kjhep.2011.17.2.130] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
18 Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol. 2012;18:3035-3049. [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
19 Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int. 2011;5:927-933. [PMID: 21484118 DOI: 10.1007/s12072-011-9266-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
20 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
21 Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015;21:7637-47. [PMID: 26167066 DOI: 10.3748/wjg.v21.i25.7637] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 44] [Article Influence: 11.4] [Reference Citation Analysis]
22 Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026. [PMID: 18768945 DOI: 10.1056/nejmoa080120910.1053/jhep.2001.22172] [Reference Citation Analysis]
23 Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol 2014;20:15499-517. [PMID: 25400435 DOI: 10.3748/wjg.v20.i42.15499] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
24 Møller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci 2015;60:3209-25. [DOI: 10.1007/s10620-015-3752-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
25 Iwamoto T, Maeda M, Hisanaga T, Saeki I, Fujisawa K, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis. Intern Med 2016;55:2911-6. [PMID: 27746425 DOI: 10.2169/internalmedicine.55.6819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
26 Gomez EV, Gonzalez AT, Bertot LC, Yasells Garcia A, Rodriguez YS, Perez YM. Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. PLoS One 2014;9:e95736. [PMID: 24755710 DOI: 10.1371/journal.pone.0095736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
27 Arase Y, Kagawa T, Tsuruya K, Sato H, Teramura E, Anzai K, Hirose S, Deguchi R, Shiraishi K, Mine T. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clin Drug Investig 2019;39:45-54. [PMID: 30284699 DOI: 10.1007/s40261-018-0714-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol 2010;16:5139-47. [PMID: 21049548 DOI: 10.3748/wjg.v16.i41.5139] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
29 Arroyo V, Fernández J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011;7:517-26. [DOI: 10.1038/nrneph.2011.96] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
30 Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol 2013;5:685-91. [PMID: 24432185 DOI: 10.4254/wjh.v5.i12.685] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
31 Baraldi O, Valentini C, Donati G, Comai G, Cuna V, Capelli I, Angelini ML, Moretti MI, Angeletti A, Piscaglia F. Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol. 2015;4:511-520. [PMID: 26558188 DOI: 10.5527/wjn.v4.i5.511] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
32 Moller S, Henriksen JH. Cardiopulmonary complications in chronic liver disease. World J Gastroenterol 2006;12:526-38. [PMID: 16489664 DOI: 10.3748/wjg.v12.i4.526] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
33 Zhang Q, Guo X, Zhao S, Pang X, Wang Y, Zhang Y, Chi B. Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients. Exp Ther Med 2016;11:1348-54. [PMID: 27073448 DOI: 10.3892/etm.2016.3037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
34 Chan AC, Fan ST. Criteria for liver transplantation in ACLF and outcome. Hepatol Int. 2015;9:355-359. [PMID: 25788183 DOI: 10.1007/s12072-014-9585-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
35 Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol. 2013;19:105-115. [PMID: 23837134 DOI: 10.3350/cmh.2013.19.2.105] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
36 Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World J Gastroenterol 2017;23:8062-72. [PMID: 29259382 DOI: 10.3748/wjg.v23.i45.8062] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
37 Bai Z, An Y, Guo X, Teschke R, Méndez-Sánchez N, Li H, Qi X. Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence. Can J Gastroenterol Hepatol 2020;2020:5106958. [PMID: 32676484 DOI: 10.1155/2020/5106958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Yang YW, Wu CH, Hu RH, Ho MC, Tsai MK, Wu YM, Lee PH. Longitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary center. Hepatol Int. 2010;4:507-510. [PMID: 20827408 DOI: 10.1007/s12072-010-9180-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
39 Zhao R, Lu J, Shi Y, Zhao H, Xu K, Sheng J. Current management of refractory ascites in patients with cirrhosis. J Int Med Res 2018;46:1138-45. [PMID: 29210304 DOI: 10.1177/0300060517735231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
40 Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026. [PMID: 18768945 DOI: 10.1056/nejmoa0801209] [Cited by in Crossref: 752] [Cited by in F6Publishing: 244] [Article Influence: 57.8] [Reference Citation Analysis]
41 Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol 2020;55:800-10. [PMID: 32388692 DOI: 10.1007/s00535-020-01691-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
42 Saxena V, Lai JC. Kidney Failure and Liver Allocation: Current Practices and Potential Improvements. Adv Chronic Kidney Dis. 2015;22:391-398. [PMID: 26311601 DOI: 10.1053/j.ackd.2015.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]